Noninvasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide
暂无分享,去创建一个
[1] S. Osman,et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. , 2003, Cancer research.
[2] J. Kopeček,et al. The Influence of Cytotoxicity of Macromolecules and of VEGF Gene Modulated Vascular Permeability on the Enhanced Permeability and Retention Effect in Resistant Solid Tumors , 2004, Pharmaceutical Research.
[3] B. Teicher,et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. , 1990, Science.
[4] A. Nomeir,et al. High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. , 2001, Journal of pharmaceutical and biomedical analysis.
[5] Zhonggui He,et al. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. , 2004, Medical science monitor : international medical journal of experimental and clinical research.
[6] J R Griffiths,et al. Monitoring pharmacokinetics of anticancer drugs: non-invasive investigation using magnetic resonance spectroscopy. , 2000, Advanced drug delivery reviews.
[7] C. Moonen,et al. Gradient-enhanced heteronuclear correlation spectroscopy. Theory and experimental aspects , 1992 .
[8] M. Leach,et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy , 2004, British Journal of Cancer.
[9] R. Gruetter,et al. In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time , 1999, Magnetic resonance in medicine.
[10] M. Knopp,et al. Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.
[11] H. Kessler,et al. Methodology and Applications of Heteronuclear and Multidimensional 13C NMR to the Elucidation of Molecular Structure and Dynamics in the Liquid State , 1995 .
[12] D Artemov,et al. Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumors. , 2001, Cancer research.
[13] C. Kennard,et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.
[14] R. Port,et al. Noninvasive Methods to Study Drug Distribution , 2003, Investigational New Drugs.
[15] H. Kessler,et al. Chapter 2 – Methodology and Applications of Heteronuclear and Multidimensional 13 C NMR to the Elucidation of Molecular Structure and Dynamics in the Liquid State , 1995 .
[16] S. Gerson,et al. Acquired resistance to O 6-benzylguanine plus chloroethylnitrosoureas in human breast cancer , 1999, Cancer Chemotherapy and Pharmacology.
[17] S. Gerson,et al. Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer. , 1999, Cancer chemotherapy and pharmacology.
[18] J. Griffiths,et al. Pharmacokinetics of the 13C labeled anticancer agent temozolomide detected in vivo by selective cross‐polarization transfer , 1995, Magnetic resonance in medicine.
[19] M. Stevens,et al. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. , 1994, Biochemistry.
[20] L. Grochow,et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] G. Margison,et al. Effect of O6‐(4‐bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model , 2002, International journal of cancer.
[22] D. Bluemke,et al. Proton magnetic resonance spectroscopic imaging of human breast cancer: A preliminary study , 2004, Journal of magnetic resonance imaging : JMRI.
[23] M. Décorps,et al. 2D‐spatial/2D‐spectral spectroscopic imaging of intracerebral gliomas in rat brain , 2000, Magnetic resonance in medicine.